



**Press release**  
June 12, 2020  
Gothenburg

## The study from Lund published in Nature Communications

**According to an article published today in the scientific journal Nature Communications, the use of the heart preservation technology developed by Professor Stig Steen is a safe method of preservation of hearts. This is an important step for XVIVO as well as, since the company's heart preservation products are based on this technology. The commercial rights to the technology are owned by XVIVO.**

Today the first scientific article was published which describes the results after storage during the transport of donated hearts using the method developed by Professor Stig Steen in Lund, and to which XVIVO has the commercial rights. The article was published in Nature Communications today and the article's first author is Professor Johan Nilsson. See below link for the article in full:

<https://www.nature.com/articles/s41467-020-16782-9>

The study describes the results for six transplant patients, that received a donated heart after it was stored during transport using the new technology. These six patients are compared with 25 patients where the donated heart is stored during transport with traditional cold preservation. After six months, all patients (100%) transplanted with the new technology are alive and without serious complications related to heart function or rejection. The corresponding outcome in the control group of 25 patients was 72%. The results show that the method is safe and functional for clinical application.

June 12, 2020  
Gothenburg  
XVIVO Perfusion AB (publ)

For further information please contact:  
Christoffer Rosenblad, CFO, +46 735 192159, [christoffer.rosenblad@xvivoperfusion.com](mailto:christoffer.rosenblad@xvivoperfusion.com)  
Dag Andersson, CEO, +46 76 643 30 31, [dag.andersson@xvivoperfusion.com](mailto:dag.andersson@xvivoperfusion.com)

---

XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation. The company is headquartered in Gothenburg, Sweden, and has one office in Lund, Sweden and one office in the USA. The Xvivo share is listed on Nasdaq Stockholm and has the ticker symbol XVIVO. More information can be found on the website [www.xvivoperfusion.com](http://www.xvivoperfusion.com).

---

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity number 556561-0424.  
Tel: +46 31 788 21 50. Fax: +46 31 788 21 69.  
E-mail: [info@xvivoperfusion.com](mailto:info@xvivoperfusion.com). Website: [www.xvivoperfusion.com](http://www.xvivoperfusion.com)

The information was submitted for publication, through the agency of the contact person set out above, at 4:30 p.m. CET on June 12, 2020.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.